Welcome

T2D is a major risk factor for micro- and macrovascular complications. It doubles CV risk, increases the risk of kidney disease and reduces life expectancy. Addressing the burden of CV events is at the core of diabetes care.

The ACROSS T2D educational slide modules examine cardiovascular and renal disease in patients with T2D.
 

Disease State

SEE ALL

Therapeutic Management

SEE ALL
  • view presentation
    Conducting and interpreting subgroup analyses

    This module explains the purpose, method, interpretation and potential

  • view presentation
    Evolving evidence-based recommendations in T2D

    This module summarises recent changes to global diabetes, cardiovascul

  • view presentation
    Patient case study - Patient with acute myocardial infarction

    This interactive module explores the care of a patient whose T2D was d

Cardiovascular Outcomes Trials

SEE ALL
  • view presentation
    Cardiovascular outcomes and cardio-renal trials with SGLT2 inhibitors in patients with T2D

    This module provides an overview of SGLT2 inhibitor clinical trials an

  • view presentation
    VERTIS CV

    The VERTIS CV trial assessed the cardiovascular safety of ertugliflozi

  • view presentation
    Kidney outcomes in SGLT2 inhibitor outcome trials in patients with T2D

    Overview of kidney outcomes in patients with T2D from SGLT2 inhibitor